Tag: submission

Adverse events were generally low-grade, transient, and readily manageable

At the initiative and by the decision of the Board of AUGA group, RAB (code 126264360, address Konstitucijos ave. 21C, Vilnius, the “Company”), it has been decided to revoke the extraordinary General Meeting of Shareholders convened on July 14, 2025, following the decision of the Vilnius Regional Court to extend the deadline for submitting the Company's restructuring plan for Court approval until August 19, 2025. This Court decision was based on unresolved issues regarding the contested creditor claims in the Company's restructuring case, which currently prevent the creditors from making decisions in accordance with the Law on Legal Entities' Insolvency (hereinafter referred to as the "Insolvency Law").

ATLANTA, July 01, 2025 (GLOBE NEWSWIRE) -- The Dr. Michael Lebow Scholarship for Future Doctors is now officially open for applications, inviting undergraduate students across the United States to compete for a one-time academic award designed to support and encourage future leaders in the healthcare field. This prestigious scholarship, created by esteemed vascular surgeon Dr. Michael Lebow, is committed to recognizing students who have demonstrated academic excellence, a passion for medicine, and a clear vision for positively impacting the healthcare industry.

EINDHOVEN, the Netherlands, July 01, 2025 (GLOBE NEWSWIRE) -- ONWARD Medical N.V. (Euronext: ONWD and US OTCQX: ONWRY), the leading neurotechnology company pioneering therapies to restore movement, function, and independence in people with spinal cord injury (SCI) and other movement disabilities, today announced the submission of two major regulatory applications for its ARC-EX System. The Company has submitted a 510(k) application to the US Food and Drug Administration (FDA) seeking clearance to expand its indication for home use. In parallel, ONWARD has filed an application with the notified body for CE Mark certification in accordance with the European Union Medical Device Regulation (MDR) to enable commercialization of the ARC-EX System in the EU. Completed in June, these submissions represent significant milestones as the Company advances its mission to bring breakthrough therapies to people with SCI around the world.

NEW YORK, June 30, 2025 (GLOBE NEWSWIRE) -- The following statement is being issued by Levi & Korsinsky, LLP: